The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chronic pain, epilepsy, and inflammatory conditions.

Synthetic cannabinoids, a class of new psychoactive substances, have emerged as a significant public health and social stability threat due to their structural diversity, rapid iteration, and stronger ...

Argent BioPharma has started formal clinical supply of its EU-GMP cannabinoid-based active pharmaceutical ingredient (API) ...

Two people were arrested after authorities say they were alerted to a large amount of synthetic cannabinoids delivered to a ...

Medical marijuana programs across Europe vary greatly but most only allow cannabis products to be dispensed through ...

Alexander Malyshev and Sarah Ganley of Carter Ledyard & Milburn LLP discuss a gray area when the 2018 Farm Bill legalized ...

As patients increasingly turn to cannabis for chronic pain, clinicians grapple with mixed evidence and a lack of high-quality ...

A powerful Senate committee has approved a bill that contains provisions hemp industry stakeholders say would devastate the ...

The senator who championed the federal legalization of hemp is now seeking to reverse much of the reform by pushing ...

Evansville authorities say they arrested two people on dealing and neglect charges after a package containing more than 10 ...

Pervasive stigma around cannabis use is leading some ER doctors to overdiagnose a rare marijuana-related syndrome.